ReviewCurrent pharmaceutical design2006
5-HT3 receptors.
Review in Current pharmaceutical design, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 3 syntheses or guidelines pooled it, 218 citations in OpenAlex.
- "Ondansetron augmentation for obsessive-compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials".European journal of clinical pharmacology · 2026Pooled it
- 5-HTCurrent neuropharmacology · 2021Pooled it
- Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis.Current medical science · 2018Pooled it
- Prevention of Pain on Propofol Injection: A Comparison of Pretreatment with 5-Hydroxytryptamine 3 Antagonists Granisetron, Ondansetron, and Ramosetron.Annals of African medicine · 2026Trial
- A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy.BMC medical genomics · 2023Trial
- HTR3A Receptor Signaling in Human Disease: From Bioelectrical Regulation to Therapeutic Targeting.Molecular neurobiology · 2026Review
- Serotonergic System Dysregulation in Alzheimer's Disease.ACS chemical neuroscience · 2026Review
- Aging Enhances Serotonergic Signaling via 5-HTAging cell · 2026Article
- Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article.Cardiovascular drugs and therapy · 2026Review
- The Aging Gut-Brain Axis: Effects of Dietary Polyphenols and Metal Exposure.Chronic diseases and translational medicine · 2025Review
- Effect of High-Rate Repetitive Transcranial Magnetic Stimulation on Phonophobia and Brainstem Auditory Evoked Potential in Migraine.Molecular neurobiology · 2025Article
- Review
- Serotonergic Regulation in Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Haloperidol, a typical antipsychotic, inhibits 5-HTThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Quetiapine competitively inhibits 5-HTThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Structural characterisation of a cysteine-rich conotoxin, sigma(σ)S-GVIIIA, extracted from the defensive venom of the marine cone snail Conus geographus.The Biochemical journal · 2025Article
- Article
- Serotonin signaling to regulate energy metabolism: a gut microbiota perspective.Life metabolism · 2025Review
- Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.Current gene therapy · 2025Review
- Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The 5-HT(3) receptor is a member of the Cys-loop family of ligand-gated ion channels. These receptors are located in both the peripheral and central nervous systems, where functional receptors are constructed from five subunits. These subunits may be the same (homopentameric 5-HT(3A) receptors) or different (heteropentameric receptors, usually comprising of 5-HT(3A) and 5-HT(3B) receptor subunits), with the latter having a number of distinct properties. The 5-HT(3) receptor binding site is comprised of six loops from two adjacent subunits, and critical ligand binding amino acids in these loops have been largely identified. There are a range of selective agonists and antagonists for these receptors and the pharmacophore is reasonably well understood. There are also a wide range of compounds that can modulate receptor activity. Studies have suggested many diverse potential disease targets that might be amenable to alleviation by 5-HT(3) receptor selective compounds but to date only two applications have been fully realised in the clinic: the treatment of emesis and irritable-bowel syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.